argenex (NASDAQ:ARGX) Price Target Raised to $1,202.00

argenex (NASDAQ:ARGX) had its price target hoisted by HC Wainwright from $940.00 to $1,202.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for argenex’s FY2027 earnings at $34.82 EPS, FY2028 earnings at $44.72 EPS, FY2029 earnings at $56.38 EPS and FY2030 earnings at $76.63 EPS.

A number of other brokerages have also commented on ARGX. Citizens Jmp cut their price target on argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a report on Friday, July 24th. Piper Sandler boosted their target price on shares of argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a research report on Monday. Wells Fargo & Company boosted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Royal Bank Of Canada upped their target price on shares of argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Citigroup increased their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,118.28.

argenex Stock Performance

argenex stock opened at $1,038.12 on Tuesday. The business’s 50-day simple moving average is $892.22 and its 200-day simple moving average is $825.72. The firm has a market capitalization of $64.94 billion, a PE ratio of 39.87, a PEG ratio of 1.09 and a beta of 0.46. argenex has a 52 week low of $658.60 and a 52 week high of $1,039.30.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Research analysts forecast that argenex will post 28.47 earnings per share for the current year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently modified their holdings of ARGX. Janus Henderson Group PLC raised its stake in shares of argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares in the last quarter. M&T Bank Corp lifted its stake in argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP lifted its stake in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Morgan Stanley boosted its holdings in argenex by 19.2% during the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after purchasing an additional 83,746 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of argenex by 390.4% in the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: HC Wainwright raised its price target to $1,202 and lifted long-term earnings forecasts. The firm increased its FY2027 EPS estimate to $34.82 from $34.38, FY2028 to $44.72 from $43.50, FY2029 to $56.38 from $53.47, and FY2030 to $76.63 from $64.39. HC Wainwright maintained its “Buy” rating, signaling confidence in argenx’s long-term growth. HC Wainwright Boosts argenx Price Target
• Positive Sentiment: Other analysts also increased their targets. Morgan Stanley raised its target to $1,230, Wedbush lifted its target to $1,150, and Citi reiterated a “Buy” rating. Citizens JMP and Piper Sandler also forecast substantial appreciation potential, reinforcing the positive analyst sentiment. Wedbush Raises argenx Price Target Morgan Stanley Raises argenx Price Target argenx Receives a Buy from Citi
• Positive Sentiment: Oppenheimer said recent myositis data helps derisk the opportunity for Vyvgart. The assessment supports investor expectations that argenx may expand Vyvgart’s commercial reach and sustain revenue growth. argenx Myositis Data Derisk Vyvgart Opportunity
• Neutral Sentiment: The stock’s valuation is elevated, with a price-to-earnings ratio near 40, so continued gains depend on argenx converting its clinical pipeline and Vyvgart opportunity into the strong earnings growth analysts now project.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.